Adalimumab Market is expected to reach USD 31,610.01 million by 2029

Published October 10, 2023

The winning Adalimumab Market survey report provides an all-inclusive study on production capacity, consumption, import and export for all major regions across the globe. The report consists of all the detailed profiles for the Adalimumab Market major manufacturers and importers who are influencing the market. According to this report the market is expected to grow at a substantial Compound Annual Growth Rate (CAGR) during the forecast period 2023-2029. This market report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the market. A worldwide Adalimumab Market analysis report speaks about the manufacturing process, type as well as applications.

In recent years, the adalimumab market is anticipated to grow rapidly during the forecast period. Adalimumab, which was first licensed in the United States, is now available in more than 60 countries. Its global market is consolidated, with only a few firms attempting to outsmart one other on price. Most of the major players are currently concentrating their efforts on the development of adalimumab biosimilars for the treatment of rheumatoid arthritis and psoriasis. This is seen in clinical trials testing the safety and efficacy of adalimumab biosimilars in the treatment of medical disorders. Many inflammatory disorders in adults are treated with adalimumab, including ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.

Data Bridge Market Research analyses that the adalimumab market was valued at USD 20,912.1 million in 2021 and is expected to reach USD 31,610.01 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request a Sample PDF:

Market Definition

Adalimumab is a prescription medicine which is sold under the brand names Humira and Exemptia. heumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis, and ulcerative colitis are all treated with adalimumab. TNF (tumour necrosis factor alpha) is commonly bound by adalimumab. When TNF interacts to TBF receptors, an inflammatory response to autoimmune illness is triggered. By binding to a TNF, adalimumab reduces the likelihood of an inflammatory response.


  • Rise in the incidence rate of  autoimmune disease

The rise in incidences of autoimmune disease such as psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and Crohn’s disease is anticipated to flourish the growth rate of the market. Along with this, the growing prevalence of chronic disorders will enhance the demand of adalimumab market.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of adalimumab market is the rising healthcare expenditure which helps in improving its infrastructure.

  • Rising geriatric population

The surging number of geriatric population will propel the market’s growth rate during the forecast period of 2022-2029. As per the World Ageing 2020 research, the world’s population will be roughly 727 million people aged 65 and up in 2020. In 2050, the number of elderly people is expected to increase to 1.5 billion. The geriatric population is more prone to chronic ailments, which is anticipated to enhance the market’s growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness and surging demand for biosimilar drugs owing to their cost-effectiveness will expand the adalimumab market. Additionally, high disposable income and rising cases of upper respiratory tract infection will result in the expansion of adalimumab market.

Recent Development

  • In October 2021, The U.S. Food and Drug Administration (FDA) had announced the approval of first interchangeable biosimilar product for the treatment of various inflammatory diseases. The biosimilar and interchangeable approval pathway was established to help patients with critical medical conditions gain access to more treatment options. Cyltezo is the first interchangeable monoclonal antibody and the second interchangeable biosimilar medicine authorized by the FDA.

Browse Complete Report Details-

Adalimumab Market Scope

Drug class

  • Antirheumatics
  • TNF Alfa Inhibitors
  • Others


  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Chronic Plaque Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Non-Infectious Intermediate
  • Others


  • Biologics
  • Biosimilars

Dosage Strength

  • 40mg/0.4mlg
  • 80mg/0.8mlg
  • 20mg/0.2mlg
  • 10mg/0.1mlg
  • Others

Drug Type

  • Branded
  • Generics

Route of Administration

  • Oral
  • Parenteral
  • Others

Dosage Form

  • Injection
  • Solution
  • Tablet
  • Others

Age Group

  • Pediatric
  • Adult
  • Geriatric


  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the this market
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Critical Insights Related to This Market Included in the Report:

  • Exclusive graphics and Illustrative SWOT analysis of some of the leading companies in this market
  • Value chain analysis of prominent players in the market
  • Current trends influencing the dynamics of this market across various geographies
  • Recent mergers, acquisitions, collaborations, and partnerships
  • Revenue growth of this industry over the forecast period
  • Marketing strategy study and growth trends
  • Growth driven factor analysis
  • Emerging recess segments and region-wise market
  • An empirical evaluation of the curve of this market
  • Ancient, Present, and Probable scope of the market from both prospect value and volume

Some of the major players operating in the adalimumab market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France), Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • Biogen (US)
  • Fresenius Kabi AG (Germany)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Amgen Inc. (US)
  • AbbVie Inc. (US)
  • Abbott (US)
  • CELLTRION INC. (South Korea)
  • Samsung Bioepis (South Korea)
  • Coherus BioSciences (US)
  • Innovent Biologics, Inc. (China)
  • Hetero Biopharma Ltd. (India)
  • Reliance Life Sciences (India)

Browse Detailed Summary of Research Report with TOC:

Adalimumab Market Regional Analysis/Insights

The adalimumab market is analysed and market size insights and trends are provided by country, drug class, type, indication, dosage form, dosage strength, drug type, route of administration, age group, end-users and distribution channel as referenced above.

The countries covered in the adalimumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the adalimumab market because of the growing geriatric population and surging prevalence of rheumatoid arthritis in this region. Additionally the rising healthcare expenditure will further propel the market’s growth rate in this region.

Top DBMR Healthcare Reports:        

Global Bipolar Disorder Treatment Market – Industry Trends and Forecast to 2029

Global Diabetic Macular Edema Treatment Market – Industry Trends and Forecast to 2029

Global 3D Cone Beam Computed Tomography (CBCT) Systems Market – Industry Trends and Forecast to 2029

Global Pregnancy Care Products Market – Industry Trends and Forecast to 2029

Global Hair and Care Market – Industry Trends and Forecast to 2030

Global Vascular Stent Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475


CDN Newswire